Zai Lab Partner Novocure's Metis Phase 3 Trial Meets Primary Endpoint In Brain Metastases
27/3 15:24
(RTTNews) - Zai Lab Ltd.'s (ZLAB) partner Novocure Ltd. (NVCR) announced on Wednesday that its phase 3 clinical trial in Tumor Treating Fields therapy for patients with 1-10 brain metastases from non-small cell lung cancer or NSCLC, has met its primary endpoint by demonstrating s...